行情

HALO

HALO

奥洛兹美医疗
NASDAQ

实时行情|Nasdaq Last Sale

41.69
+1.27
+3.14%
盘后: 41.69 0 0.00% 16:44 05/16 EDT
开盘
40.79
昨收
40.42
最高
42.35
最低
40.48
成交量
132.09万
成交额
0
52周最高
46.62
52周最低
31.36
市值
57.51亿
市盈率(TTM)
13.97
分时
5日
1月
3月
1年
5年
Is Galapagos (GLPG) Outperforming Other Medical Stocks This Year?
Here is how Galapagos NV (GLPG) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks · 8小时前
Is Halozyme Therapeutics (HALO) a Smart Long-Term Buy?
Bernzott Capital Advisors, an investment management firm, published its “US Small Cap Value Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. The portfolio fell -4.6% (gross), modestly below the Russell 2000 Value’s decline...
Insider Monkey · 4天前
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Zacks · 5天前
--JMP Securities Raises Halozyme Therapeutics Price Target to $58 From $55, Maintains Market Outperform Rating
MT Newswires · 5天前
Recap: Halozyme Therapeutics Q1 Earnings
Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 5天前
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6天前
Halozyme Therapeutics Q1 EPS $0.47 Misses $0.49 Estimate, Sales $117.30M Miss $128.25M Estimate
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.49 by 4.08 percent. This is a 27.03 percent increase over earnings of $0.37 per share
Benzinga · 6天前
BRIEF-Halozyme Reports First Quarter 2022 Results
reuters.com · 6天前
更多
暂无数据
了解HALO最新的财务预测,通过HALO每股收益,每股净资产,每股现金流等数据分析奥洛兹美医疗近期的经营情况,然后做出明智的投资选择。
分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

10.00%强力推荐
70.00%买入
10.00%中性
0.00%落后大盘
10.00%卖出
目标价格预测
分析师预测HALO价格均价为48.75,最高价位62.00,最低价为19.00。
最高62.00
均价48.75
最低19.00
现价41.69
EPS
实际EPS
预期EPS
0.170.330.490.66
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
机构持股
总机构数: 436
机构持股: 1.52亿
持股比例: 110.66%
总股本: 1.38亿
类型机构数股数
增持
124
441.87万
建仓
39
261.55万
减持
117
572.10万
平仓
41
246.77万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.23%
制药与医学研究
+1.02%
高管信息
Non-Executive Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Nicole Labrosse
Senior Vice President/Chief Technology Officer
Michael Labarre
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Mark Snyder
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Moni Miyashita
Independent Director
Matthew Posard
暂无数据
暂无数据
HALO 简况
Halozyme Therapeutics Inc是一家生物制药技术平台公司。该公司将其技术授权给生物制药公司,并联合进行产品开发,其产品结合了ENHANZE给药技术以及合作方的化合物。该公司的先导酶rHuPH20用于促进注射药物和液体的输送。该公司及其合作方已获批的产品和候选产品均以rHuPH20为基础,rHuPH20是一种专利型重组人透明质酸酶。该公司的主导产品Hylenex重组是一种rHuPH20制剂,可促进皮下输液,实现水合作用,并促进其他注射药物的分散和吸收,并在皮下尿路造影中改善不透射线药物的吸收。其在研产品包括Herceptin SC、HYQVIA、DARZALEX等。

微牛提供Halozyme Therapeutics, Inc.(NASDAQ-HALO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的HALO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易HALO股票基本功能。